Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

被引：0
作者：
Hidekatsu Nakai
Noriomi Matsumura
机构：
[1] Kindai University,Department of Obstetrics and Gynecology, Faculty of Medicine
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Ovarian cancer; Molecularly targeted drug; PARP inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With the development of poly(ADP-ribose) polymerase inhibitors, the treatment of advanced ovarian cancer is changing dramatically. The purpose of this narrative review is to provide a direction for the individualization of advanced ovarian cancer treatment based on the mechanism of action of molecularly targeted drugs currently used in Japan. The PAOLA-1 study showed very good progression-free survival in patients with homologous recombination deficiency tumors who underwent complete surgery with primary debulking surgery and who received olaparib plus bevacizumab. Niraparib has high intratumor penetration, and in a subgroup analysis of the PRIMA study, it was most effective in patients with residual tumors after interval debulking surgery. These data suggest the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized.
引用
收藏
页码：1001 / 1012
页数：11
相关论文
共 133 条
[11]  
Langelier MF(2019)Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA Trial J Clin Oncol 37 2968-3537
[12]  
Velagapudi UK(2021)Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 22 1721-2428
[13]  
Sun K(2020)Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 Trial J Clin Oncol 38 3528-422
[14]  
Mikule K(2019)Olaparib plus bevacizumab as first-line maintenance in ovarian cancer N Engl J Med 381 2416-A14
[15]  
Wang Z(2020)Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course Gynecol Oncol 156 415-S1164
[16]  
Patch AM(2020)Maintenance olaparib plus bevacizumab after platinum-based chemotherapy plus bev in patients with newly diagnosed advanced high-grade ovarian cancer: Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial J Clin Oncol 38 6039-2402
[17]  
Christie EL(2020)Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial Int J Gynecol Cancer 30 A13-2415
[18]  
Etemadmoghadam D(2020)Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma: final analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial Ann Oncol 31 S1163-8054
[19]  
Borst P(2019)Niraparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 381 2391-2783
[20]  
Schinkel AH(2021)Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study Gynecol Oncol 162 S65-783
12345678910